Those cell lines were invasive, insensitive to the cytostatic effects of TGF-β, but responsive to TGF-β activation and could mimic certain late stages HCC in the clinic, particularly those previously treated with sorafenib. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.